Shares of Valeritas Holdings Inc (NASDAQ:VLRX) jumped Wednesday after releasing more data underscoring the quality and performance of its flagship V-Go Wearable Insulin Delivery device.
Valeritas’ stock recently traded up 6.6% to $4.02 a share on heavier-than-average volume. In pre-market trading, shares rose as high as 31%.
The Bridgewater, New Jersey, medical-tech company said the data demonstrate that the V-Go therapy resulted in better glycemic control and improved attainment of quality performance measures, and was well tolerated by patients.
The data were pulled from the VERDICT study -- a real-world retrospective analysis of electronic health records from a large specialized diabetes center -- and announced at the International Society for Pharmacoeconomics and Outcomes Research's annual meeting in New Orleans, according to a statement.
“The VERDICT study demonstrates that significantly more patients achieved better control and attained improved quality metrics," said CEO John Timberlake. “We will continue to partner with clinicians to improve patient outcomes and quality of care delivered using V-Go as a standard way to deliver basal-bolus insulin therapy.”
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham